학술논문
Phase 1b/2a Study of AZD4573 (CDK9i) and Acalabrutinib in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL): Results from Dose-Escalation
Document Type
Abstract
Author
Source
In Blood 15 November 2022 140 Supplement 1:6656-6658
Subject
Language
ISSN
0006-4971